Dubai: The pharma giant Novartis has entered a strategic partnership with UAE’s Pharmax Pharmaceuticals. This covers the commercialization and co-marketing of Novartis products to Pharmax to enhance patient access to medicines and treatments for cardio-metabolic diseases such as diabetes and hypertension.
“Novartis is on a mission to reimagine medicine and improve and extend people’s lives,” said Mohamed Ezz Eldin, President and Head of Gulf Cluster, Novartis Pharmaceuticals. “We cannot do that alone. We continually seek out like-minded partners such as Pharmax to support us in our efforts.”
The companies formalized their partnership at a ceremony held at the Swiss Pavilion. Present were Massimo Baggi, Ambassador of Switzerland to UAE and Bahrain; Marwan Abdul Aziz, Managing Director at Dubai Science Park; Ezz Eldin; Fahad Al Qassim, Chairman of Pharmax, and Madhukar Tanna, CEO at Pharmax Pharmaceuticals.
The agreement will cover the commercialization of oral antidiabetic and oral antihypertensive medicines to enhance care and treatment outcomes for these conditions.
According to Tanna, "UAE is not immune to high prevalence of lifestyle diseases and such efforts will expand choice of treatment for physicians and patients both. We believe this step will pave the way for improving market access of many new and innovative medicines here in UAE.”
